Trial Profile
Observational study for treatment outcome in patients with HER2-positive metastatic breast cancer who received pertuzumab combination chemotherapy.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 15 May 2020
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Antineoplastics
- Indications Advanced breast cancer
- Focus Adverse reactions
- 10 May 2020 Status changed from recruiting to discontinued.
- 13 Nov 2013 New trial record